Targeting androgen receptor aberrations in castration-resistant prostate cancer
A Sharp, J Welti, J Blagg, JS de Bono - Clinical Cancer Research, 2016 - AACR
A Sharp, J Welti, J Blagg, JS de Bono
Clinical Cancer Research, 2016•AACRAndrogen receptor (AR) splice variants (SV) have been implicated in the development of
metastatic castration-resistant prostate cancer and resistance to AR targeting therapies,
including abiraterone and enzalutamide. Agents targeting AR-SV are urgently needed to test
this hypothesis and further improve the outcome of patients suffering from this lethal disease.
Clin Cancer Res; 22 (17); 4280–2.© 2016 AACR. See related article by Yang et al., p. 4466
metastatic castration-resistant prostate cancer and resistance to AR targeting therapies,
including abiraterone and enzalutamide. Agents targeting AR-SV are urgently needed to test
this hypothesis and further improve the outcome of patients suffering from this lethal disease.
Clin Cancer Res; 22 (17); 4280–2.© 2016 AACR. See related article by Yang et al., p. 4466
Abstract
Androgen receptor (AR) splice variants (SV) have been implicated in the development of metastatic castration-resistant prostate cancer and resistance to AR targeting therapies, including abiraterone and enzalutamide. Agents targeting AR-SV are urgently needed to test this hypothesis and further improve the outcome of patients suffering from this lethal disease. Clin Cancer Res; 22(17); 4280–2. ©2016 AACR.
See related article by Yang et al., p. 4466
AACR